If you’re wanting to invest in growth shares but aren’t sure which ones to buy, then you might want to consider exchange traded funds (ETFs).

There are a number of ETFs out there that allow investors to buy a slice of some high quality growth shares through a single investment. Two such ETFs that will allow you to achieve this are listed below:

BetaShares Asia Technology Tigers ETF (ASX: ASIA)

The first ETF for growth investors to look at is the BetaShares Asia Technology Tigers ETF. It gives investors exposure to approximately 50 of the most promising tech companies in the Asian market but excluding Japan. Among the fund’s top holdings you will find tigers such as Alibaba, Baidu, Infosys, JD.com, Kuaishou Technology, Meituan Dianping, Pinduoduo, Samsung, Tencent.

In respect to Pinduoduo, it is an ecommerce platform that offers a wide range of products. This includes everything from daily groceries to home appliances. Pinduoduo connects distributors with consumers directly through an interactive shopping experience and allows the latter to team up to buy items in bulk at lower prices. At the last count, the company had a massive 880 million active customers.

BetaShares Global Cybersecurity ETF (ASX: HACK)

Another ASX ETF for growth shares to consider is the BetaShares Global Cybersecurity ETF. As its name implies, this ETF gives investors exposure to the leading companies in the global cybersecurity sector.

Among the growth shares included in the fund are global cybersecurity giants and emerging players from a range of global locations. Both of which look well-positioned to benefit from the increasing demand for cybersecurity services as cyber attacks increase. Among the companies you’ll be buying a piece of are Accenture, Cisco, Cloudflare, Crowdstrike, Okta, and Splunk.

In respect to CrowdStrike, it is a provider of incident response and forensic analysis services via its Falcon platform. Its services are designed to help businesses understand whether a breach has occurred. It then allows the user to respond and recover from a breach with speed and precision to remediate the threat.

The post 2 top ETFs for ASX growth investors to buy in July appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 3 excellent ETFs for ASX investors to buy in July
• Can the ASX-listed HACK ETF provide exposure to shares fighting what Warren Buffett calls the ‘number one problem with mankind’?
• 3 highly rated ETFs for ASX investors to buy now
• Down 23% since mid-April, is the HACK ETF a golden opportunity?
• 2 popular ETFs for ASX investors to buy next week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BETA CYBER ETF UNITS. The Motley Fool Australia has positions in and has recommended BETA CYBER ETF UNITS. The Motley Fool Australia has recommended BetaShares Asia Technology Tigers ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/KyXPVnu

The Altium Limited (ASX: ALU) share price spiked more than 4% into the green on Wednesday to close at $28.67.

Investors rallied Altium shares higher on no news. However, in broader market moves, the S&P/ASX All Technology Index (ASX: XTX) powered 3.2% higher today.

Who owns Altium shares?

The software company has 131.5 million outstanding shares on issue and these are distributed among 31,572 shareholders, according to Bloomberg data.

The majority of these investors own a range of one to 1,000 shares, whereas just 47 parties own 100,000 or more shares.

However, the top 20 shareholders of the company hold more than 76% of all the shares on issue.

Of the nine directors listed, six have equity positions in Altium via direct and/or indirect share ownership, according to Bloomberg.

Collectively, these directors hold a 9.67% indirect stake in the company (as some holdings may yet to be realised in the form of deferred equity).

An entity related to CEO Aram Mirkazemi owns a collective 9.63 million shares. Additionally, recent on-market transactions from non-executive director Simon Kelly have settled each month from February to April 2022.

Kelly has bought 8,081 shares in 2022 and spent $257,537 in doing so. Certainly, the Altium non-executive director believes in the ASX tech company’s future prospects.

Altium share price snapshot

In the last 12 months, the Altium share price has slipped more than 20% into the red. It has fallen 36% this year to date.

At the current share price, Altium has a market capitalisation of $3.76 billion.

The post What percentage of Altium shares are owned by insiders? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX shares today
• Why are ASX 200 tech shares sprinting higher today?
• Analysts name 2 ASX growth shares to buy this week
• Experts say these ASX 200 growth shares are buys with 20%+ upside
• Why is the Altium share price down 5% today?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Altium. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/4G5QYcp

The Qantas Airways Limited (ASX: QAN) share price closed down slightly today as news of worker strikes emerged.

Qantas shares dropped 0.22% today to $4.48 at market close. For perspective, the S&P/ASX 200 Index (ASX: XJO) fell more than the airline today, slipping 0.53%. Flight Centre Travel Group (ASX: FLT) also slipped 0.29% but Webjet Limited (ASX: WEB) shares jumped 1.3%.

Let’s take a look at what is happening at Qantas.

Engineers could strike

Qantas aircraft engineers are considering strike action within weeks due to pay negotiations stalling, The Age reported.

A vote on potential strike action is earmarked for August if requests for a pay rise as high as 12% are not met, the publication reported. Australian Licensed Aircraft Engineers Association federal secretary Steve Purvinas said:

The airline has not taken negotiations seriously. There have been years of meetings and no progress.

However, in a statement, Qantas has expressed concern regarding planned action. The airline highlighted it has “contingency plans” to reduce disruptions. A Qantas Group spokesperson said:

With the industry still recovering from the impact of the pandemic, the last thing it needs is the threat of industrial action.

This action from the union is completely unnecessary.

Meanwhile, ASX travel shares have performed relatively well against the S&P/ASX 200 Index (ASX: XJO) benchmark today.

This comes amid new travel rules that apply from 6 July. A COVID-19 vaccine is no longer required for international tourists arriving in Australia. The digital passenger declaration form has also been ditched for now.

Commenting on the news, Health Minister Mark Butler said on Sunday:

The chief medical officer has advised it is no longer necessary for travellers to declare their vaccine status as part of our management of COVID

Share price snapshot

The Qantas share price has descended nearly 9% in the past year, while it is nearly 11% in the red year to date.

For perspective, the ASX 200 has shed nearly 9% in a year.

In the past five years, Qantas shares have lost 22%.

The post Qantas share price slides as engineers plan strike action appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why did the Qantas share price outperform the ASX 200 in FY22?
• How did ASX travel shares perform in June?
• ASX 200 travel shares leap as Australia scraps COVID-19 vaccine mandates for international arrivals
• Top brokers name 3 ASX shares to buy next week
• Why did the Qantas share price plunge 19% in June?

Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/BxSIKjk

The Race Oncology Ltd (ASX: RAC) share price had yet another stunning day, leaving the broader index well behind.

At close of trade, the specialty pharmaceutical company’s shares finished 15.74% ahead at $2.50 each. This means the company’s shares have now risen more than 38% in the past month.

For context, the All Ordinaries Index (ASX: XAO) closed 0.5% lower to 6,784.3 points today and is now down more than 9% for the month.

What’s driving Race Oncology shares forward?

Investors were rallying up the Race Oncology share price today amid the company’s latest string of announcements, along with positive sentiment.

Last month, the company advised it was conducting a share buyback to increase shareholder value.

The board approved the purchase of up to four million Race Oncology shares, which represents 2.5% of its issued capital.

When the news broke, this led shares in the company to finish 11.24% higher on the day.

Furthermore, Race Oncology released a statement highlighting two peer-reviewed abstracts published in the scientific journal, Cancer Research.

Both publications noted the company’s new preclinical data on the anti-cancer uses of its lead candidate Zantrene.

Again, when Race Oncology provided the update to the ASX, its shares soared 10% before market close.

After that, there was another rush on the company’s shares following successful results from its Zantrene trial.

The clinical data showed that the anti-cancer drug protected the hearts of mice from chemotherapy damage.

This is particularly significant as the company is seeking to capture the “large commercial opportunity” that’s present for Zantrene.

Lastly, helping the accent of Race Oncology shares is the S&P/ASX 200 Health Care (ASX: XHJ) sector advancing 1.97% today.

About the Race Oncology share price

Despite the strong gains made over the month, the Race Oncology share price is down 30% in 2022.

This is due to extreme market volatility impacting ASX shares amid rampant inflation, interest rate hikes, and a downbeat economic outlook.

Based on today’s price, Race commands a market capitalisation of around $398 million.

The post Up 38% in a month, what’s sparking the recent Race Oncology share price run-up? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• ASX 200 healthcare shares provided some pain relief today. Here’s why
• Why is the Race Oncology share price soaring 13% today?
• Why did the Race Oncology share price rocket 10% today?
• Race Oncology share price soars 16% on buyback news

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/GIQ3V6k